Literature DB >> 9849494

Effects of ondansetron on gastrointestinal symptoms in carcinoid syndrome.

A N Wymenga1, E G de Vries, M K Leijsma, I P Kema, J H Kleibeuker.   

Abstract

The effect of short-term treatment with the highly selective serotonin receptor antagonist ondansetron on symptoms and gastric emptying in 11 carcinoid patients was studied. Diarrhoea improved in 6 of 6 patients, nausea in 3 of 4 patients. Flushing was not affected. The rate of gastric emptying increased during ondansetron treatment (P = 0.08). No changes in serotonin in platelets and urinary excretion of 5-hydroxyindoleacetic acid were found. It is concluded that ondansetron can improve gastrointestinal symptoms in carcinoid patients and possibly slows gastric emptying.

Entities:  

Mesh：

Substances：

Year:  1998        PMID： 9849494     DOI： 10.1016/s0959-8049(98)00009-4

Source DB:  PubMed          Journal:  Eur J Cancer        ISSN： 0959-8049            Impact factor:   9.162


  8 in total

1.  Oral Ondansetron Offers Effective Antidiarrheal Activity for Carcinoid Syndrome Refractory to Somatostatin Analogs.

Authors:  Barbara Kiesewetter; Heying Duan; Wolfgang Lamm; Alexander Haug; Philipp Riss; Andreas Selberherr; Christian Scheuba; Markus Raderer
Journal:  Oncologist       Date:  2018-08-31

Review 2.  Fibrosis and carcinoid syndrome: from causation to future therapy.

Authors:  Maralyn Druce; Andrea Rockall; Ashley B Grossman
Journal:  Nat Rev Endocrinol       Date:  2009-05       Impact factor: 43.330

3.  Effects of ondansetron on gastric tone and motility changes induced by a prolonged intraduodenal infusion of nutrients. Results of a placebo-controlled study.

Authors:  Guillaume Savoye; Maud Brung-Lefebvre; Mickael Bouin; Céline Maillot; Philippe Denis; Philippe Ducrotté
Journal:  Dig Dis Sci       Date:  2007-03-28       Impact factor: 3.199

Review 4.  Carcinoid Syndrome and Hyperinsulinemic Hypoglycemia Associated with Neuroendocrine Neoplasms: A Critical Review on Clinical and Pharmacological Management.

Authors:  Francesca Spada; Roberta E Rossi; Elda Kara; Alice Laffi; Sara Massironi; Manila Rubino; Franco Grimaldi; Sherrie Bhoori; Nicola Fazio
Journal:  Pharmaceuticals (Basel)       Date:  2021-06-04

5.  Management of the hormonal syndrome of neuroendocrine tumors.

Authors:  Paweł Gut; Joanna Waligórska-Stachura; Agata Czarnywojtek; Nadia Sawicka-Gutaj; Maciej Bączyk; Katarzyna Ziemnicka; Jakub Fischbach; Kosma Woliński; Jarosław Kaznowski; Elżbieta Wrotkowska; Marek Ruchała
Journal:  Arch Med Sci       Date:  2016-06-01       Impact factor: 3.318

Review 6.  Advances in the Diagnosis and Management of Well-Differentiated Neuroendocrine Neoplasms.

Authors:  Johannes Hofland; Gregory Kaltsas; Wouter W de Herder
Journal:  Endocr Rev       Date:  2020-04-01       Impact factor: 19.871

Review 7.  Update on Pathophysiology, Treatment, and Complications of Carcinoid Syndrome.

Authors:  Dominique Clement; John Ramage; Raj Srirajaskanthan
Journal:  J Oncol       Date:  2020-01-21       Impact factor: 4.375

Review 8.  Spotlight on telotristat ethyl for the treatment of carcinoid syndrome diarrhea: patient selection and reported outcomes.

Authors:  Cristina Saavedra; Jorge Barriuso; Mairéad G McNamara; Juan W Valle; Angela Lamarca
Journal:  Cancer Manag Res       Date:  2019-08-08       Impact factor: 3.989
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.